Journal of geriatric oncology最新文献

{"title":"Supporting older adults with cancer and their support person through geriatric assessment and remote exercise and education: The SOAR study protocol.","authors":"Nirusha Jebanesan, Shabbir M H Alibhai, Daniel Santa Mina, Jennifer Jones, Nicholas Legacy, Laura Freeman, Ainslee Smith, Saul Cobbing, Neera Vadali, Shiuhang Lo, Kian Godhwani, Ferozah Nasiri, Maryjo Antonio, Douglas Stephens, Eric Pitters, Fay Bennie, Anne Stephens, Janet Papadakos, Linda Cerrulo, Margaret Zjadewicz, Raymond Jang, Lawson Eng, Monika Krzyzanowska, Andrew Matthew, Sara Durbano, Rajin Mehta, Ines Menjak, Urban Emmenegger, Schroder Sattar, Virginia Sun, Katherina Ladham, Martine Puts","doi":"10.1016/j.jgo.2025.102194","DOIUrl":"https://doi.org/10.1016/j.jgo.2025.102194","url":null,"abstract":"<p><strong>Introduction: </strong>Frail older adults receiving cancer treatment are at heightened risk of adverse outcomes. Despite the known benefits of exercise during cancer treatment to improve well-being, few exercise studies focus on frail older adults receiving cancer treatment and their support person. Geriatric assessment (GA) is often recommended prior to the start of treatment for frail adults with cancer, but combining the GA with a planned exercise regimen remains unexplored. This study aims to determine the feasibility and acceptability of implementing geriatric assessment and management (GAM) in combination with virtual chair-based exercise (CBE) and health education for frail older adults with cancer and their support persons.</p><p><strong>Materials and methods: </strong>This phase 2 randomized controlled trial will include patients aged 70 years and above with a lung, gastrointestinal, or genitourinary cancer referred for first- or second-line chemotherapy, immunotherapy, or targeted therapy. Patients must be frail (≥3 on the Vulnerable Elders Survey), sedentary on the Godin Leisure Time Activity Questionnaire (<90 min of moderate/intense activity per week), have English proficiency with ability to consent, a physician-estimated life expectancy of at least six months, and deemed safe to exercise. Each older adult will be invited to bring a support person to participate in the study. Patients will be randomized 1:1 to GAM combined with online CBE and health education for 12 weeks or waitlist control. Participating support persons will follow the same intervention group. Primary endpoints for feasibility and acceptability will be recruitment rate, retention, adherence, and data collection. Outcome measures include physical activity, function, fatigability, quality of life, treatment toxicity, and unplanned hospital visits. Outcome measures will be used to obtain estimates of the effect size and feasibility analysis needed for designing a phase 3 study. The study will take place at two hospitals in Toronto, Canada.</p><p><strong>Discussion: </strong>This study will investigate the feasibility, acceptability, and obtain preliminary estimates of the outcomes of GAM plus CBE and health education in preventing functional decline and improving quality of life in frail older adults receiving cancer treatment and their support persons. The results will help to design a definitive phase 3 randomized controlled trial.</p><p><strong>Trial registration: </strong>The trial is registered at ClinicalTrials.gov (Registration Number: NCT05509751).</p>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":" ","pages":"102194"},"PeriodicalIF":3.0,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remarks regarding the predictive ability of the Cancer and Aging Research Group chemotherapy toxicity calculator in haematologic malignancy","authors":"Cristian Orlando Porras Bueno ,&nbsp;Miguel Oswaldo Cadena Sanabria ,&nbsp;Miguel Enrique Ochoa Vera ,&nbsp;Angela Maria Peña Castellanos ,&nbsp;Luis Antonio Salazar Montaña ,&nbsp;Manuel Leonidas Rosales Acevedo ,&nbsp;María Lucrecia Luna González ,&nbsp;Claudia Lucia Sossa Melo","doi":"10.1016/j.jgo.2025.102193","DOIUrl":"10.1016/j.jgo.2025.102193","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102193"},"PeriodicalIF":3.0,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness and cardiovascular safety of abiraterone versus enzalutamide amongst older patients diagnosed with metastatic castration-resistant prostate cancer","authors":"Charles E. Gaber ,&nbsp;Ebere Okpara ,&nbsp;Abdullah I. Abdelaziz ,&nbsp;Jyotirmoy Sarker ,&nbsp;Kent A. Hanson ,&nbsp;Lubna Hassan ,&nbsp;Fang-Ju Lin ,&nbsp;Todd A. Lee ,&nbsp;Natalie M. Reizine","doi":"10.1016/j.jgo.2024.102148","DOIUrl":"10.1016/j.jgo.2024.102148","url":null,"abstract":"<div><h3>Introduction</h3><div>Abiraterone and enzalutamide are both approved in the United States for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The objective of this study was to compare the real-world effectiveness and cardiovascular safety of these agents, drawing from a cohort of older adult patients diagnosed with mCRPC.</div></div><div><h3>Materials and methods</h3><div>The Surveillance, Epidemiology, and End Results-Medicare database was used to conduct an observational study comparing three-year overall survival and one-year risk of major adverse cardiovascular events (MACE) between initiators of abiraterone or enzalutamide between September 2012 and June 2017. Inverse-probability-of-treatment weighting was used to balance measured confounders. MACE was defined as a hospitalization for myocardial infarction, heart failure, or ischemic event (stroke or transient attack). Results were additionally stratified by levels of a claims frailty index (robust, prefrail, frail) and the presence of baseline cardiovascular comorbidities.</div></div><div><h3>Results</h3><div>The study population consisted of 4622 male adults 66 years of age and older diagnosed with mCRPC, of which 2430 initiated abiraterone and 2192 enzalutamide. The adjusted three-year overall survival was lower in patients initiating abiraterone (27.9 %) than enzalutamide (31.5 %) (adjusted survival difference [aSD] = −3.6 %, 95 % CI: −6.2 %, −0.9 %). In frailty-stratified analysis, no survival difference was found for the robust (aSD = 0.6 %, 95 % CI: −5.0 %, 6.3 %) or frail (aSD = −1.2 %, 95 % CI: −6.1 %, 3.7 %) subgroups, but there was lower survival with abiraterone for the prefrail group (aSD = −5.9 %, 95 % CI: −9.6, −2.3). The adjusted one-year risk of MACE was higher in abiraterone initiators (5.5 %) than enzalutamide initiators (3.6 %) (adjusted risk difference [aRD] = 1.8 %, 95 % CI: 0.6 %, 3.1 %); the increase was significant in the frail (aRD = 4.8 %, 95 % CI = 1.4 %, 8.3 %) and pre-frail subgroups (aRD =1.9 %, 95 % CI: 0.1 %, 3.6 %) but not the robust subgroup (aRD = −0.3 %, 95 % CI: −1.8 %, 1.2 %).</div></div><div><h3>Discussion</h3><div>The three-year survival of abiraterone initiators was slightly lower than that of enzalutamide initiators, though the agents showed similar survival for patients with robust fitness. A one-year increase in MACE risk was observed in abiraterone initiators, especially amongst frail individuals, highlighting the importance of assessing frailty during therapy selection.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102148"},"PeriodicalIF":3.0,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Technology ownership, use, and perceptions of web-based program design features for older adults prescribed oral anticancer medication","authors":"Victoria K. Marshall ,&nbsp;Melody N. Chavez ,&nbsp;Tina M. Mason ,&nbsp;Martine Extermann ,&nbsp;Lanie A. Simon ,&nbsp;Jay Ligatti ,&nbsp;Usha Menon ,&nbsp;Laura A. Szalacha","doi":"10.1016/j.jgo.2025.102190","DOIUrl":"10.1016/j.jgo.2025.102190","url":null,"abstract":"<div><h3>Introduction</h3><div>Older adults are often prescribed oral anticancer agents (OAAs). Technology-based interventions may offer medication and symptom support. We aimed to evaluate technology ownership, use, and preferred design features of a supportive web-based program using a multimethod design utilizing surveys and semi-structured interviews.</div></div><div><h3>Materials and Methods</h3><div>Patients were recruited from a National Cancer Institute-designated Comprehensive Cancer Center. Eligibility included those: (1) ≥65 years of age; (2) prescribed a Food and Drug Administration-approved OAA; (3) English speaking; (4) able/willing to complete telephone interviews. Interviews were audio-recorded and transcribed verbatim. Cohen's Kappa was used to evaluate inter-rater reliability and calculated at 0.87.</div></div><div><h3>Results</h3><div>Participants (<em>N</em> = 30) were predominantly female (70 %), White (83.3 %), with metastatic disease (90 %). The mean age was 74.9 years. Ninety percent owned a smartphone, 66.7 % owned a tablet, and 90 % owned a computer. Nearly 57 % reported using smartphones frequently for cancer-related purposes. Four themes with corresponding subthemes were identified: (1) comfort with technology; (2) reasons for technology use for health-related purposes (research of cancer, cancer treatment, and related symptoms/side effects; using the portal to manage health; and appointment and medication reminders); (3) recommended design features for a web-based program (OAA medication-specific information; calendars &amp; medication alarms/reminders; symptom management &amp; symptom trackers; and tutorials and testimonials); and (4) adaptations for older adults (simple navigation; larger font; use of layperson's terms; use of pictures, graphics, and color coding; and voice activation).</div></div><div><h3>Discussion</h3><div>Older adults use technology for health-related purposes. Specific web-design features and adaptations are needed to enhance usability among older adults.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102190"},"PeriodicalIF":3.0,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protocol of a decisional intervention for older adults with newly diagnosed acute myeloid leukemia and their caregivers: UR-GOAL 3.","authors":"Kah Poh Loh, Qiao Ming Rachel Ng, Supriya G Mohile, Sally Norton, Ronald M Epstein, Michael B Sohn, Daniel Richardson, Omer Jamy, Soroush Mortaz Hedjri, Rachel Blumberg, Laura Nafis, Marielle Jensen-Battaglia, Ying Wang, Jason Mendler, Jane Liesveld, Eric J Huselton, Rachel Rodenbach, Jozal Moore, Craig Maguire, Steve M Buechler, Steve Hodges, Heidi D Klepin","doi":"10.1016/j.jgo.2025.102187","DOIUrl":"https://doi.org/10.1016/j.jgo.2025.102187","url":null,"abstract":"<p><strong>Introduction: </strong>Therapeutic advances have allowed more adults aged ≥60 years with acute myeloid leukemia (AML) to receive life-prolonging treatments, with improvement in overall survival. In contrast to other cancers, the onset of AML is often sudden, high-risk treatment decisions must be made quickly, and survival is often compromised due to aging-related conditions (e.g., functional impairments). Studies have demonstrated that up to 78 % of older adults with AML and their caregivers experience significant psychological distress. Distress is associated with poor quality of life, increased healthcare utilization, and increased mortality. Shared decision making (SDM) can reduce patient and caregiver distress and is essential to achieve goal-concordant care. Therefore, interventions to alleviate distress and optimize SDM in older adults with AML and their caregivers are needed. We will conduct a multicenter randomized controlled trial to evaluate the efficacy of University of Rochester-Geriatric Oncology assessment for Acute myeloid Leukemia (UR-GOAL) compared to an attention control for reducing patient distress and improving observed SDM, patient-perceived SDM, and decisional conflict.</p><p><strong>Material and methods: </strong>We will recruit 300 patients aged ≥60 years with newly diagnosed AML, their caregivers (one caregiver per patient when available), and up to 40 oncologists from four institutions: (1) Patients will view an educational video about AML diagnosis, treatment, and prognosis; complete the Best Worst Scaling values clarification process; and review a summary report of their values with tailored question prompts and resources; (2) Caregivers will view the same educational video and receive the same summary report as patients; and (3) Oncologists will review a summary report of the patient's aging-related conditions, perception of prognosis, and values. Patients, caregivers, and oncologists will then meet during clinical visits to discuss aging-related conditions, prognosis, and patient values, and reach a treatment decision. The primary outcome measure is distress (Distress Thermometer). Secondary outcome measures include observed SDM, patient perceived SDM, and decisional conflict.</p><p><strong>Discussion: </strong>This study will address significant knowledge gaps related to reducing distress and decisional conflict and improving SDM in older adults with AML. If successful, this research will inform future decisional interventions for a broader group of patients.</p>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":" ","pages":"102187"},"PeriodicalIF":3.0,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment outcomes in older patients presenting to a radiation oncology clinic based on an electronic health record-based frailty index.","authors":"Ryan T Hughes, Niema B Razavian, Claire M Lanier, Michael K Farris","doi":"10.1016/j.jgo.2025.102192","DOIUrl":"10.1016/j.jgo.2025.102192","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":" ","pages":"102192"},"PeriodicalIF":3.0,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Compounding strain: The impact of caregiver strain on health outcomes in older adults with new cancer diagnoses","authors":"Jamie M. Smith ,&nbsp;Bian Liu ,&nbsp;J. Nicholas Odom ,&nbsp;Katherine A. Ornstein ,&nbsp;Erin E. Kent","doi":"10.1016/j.jgo.2025.102191","DOIUrl":"10.1016/j.jgo.2025.102191","url":null,"abstract":"<div><h3>Introduction</h3><div>We sought to examine the association between pre-existing caregiving strain levels and care recipient health outcomes following a new cancer diagnosis.</div></div><div><h3>Materials and Methods</h3><div>We used the National Health and Aging Trends Study (NHATS) linked with the National Study of Caregiving (NSOC) and Medicare claims to identify older adults receiving family caregiving within one year before an index cancer diagnosis. Caregiving strain was determined using NSOC items of self-reported emotional, physical, and financial difficulties measured before the cancer diagnosis. We used care recipient NHATS responses to determine outcomes with the Patient Health Questionnaire-2 (PHQ-2), Generalized Anxiety Disorder Scale (GAD-2), and self-reported general health pre and post-cancer diagnoses. Multivariable logistic regression models were used to examine care recipient's health outcomes following cancer diagnosis by previously existing caregiver strain levels.</div></div><div><h3>Results</h3><div>We identified 584 caregivers who had completed the NSOC items related to caregiving strain and were linked to 404 care recipients whose index cancer diagnoses occurred in the year following the NSOC interview. Care recipients with highly strained caregivers were more likely to report anxiety than recipients with less strained caregivers (33.5 % vs. 22.9 %, <em>p</em> &lt; 0.05). In adjusted models, high strain was associated with increased odds of recipient anxiety (aOR: 2.08, 95 % CI 1.14–3.79). Depressive symptoms and general health outcomes did not differ by caregiver strain in adjusted models.</div></div><div><h3>Discussion</h3><div>The presence of caregiver strain may contribute to worsening care recipient anxiety following a new cancer diagnosis. Strategically placed caregiver screenings early in the cancer care planning could identify strained caregivers who may benefit from targeted support and training. and support.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102191"},"PeriodicalIF":3.0,"publicationDate":"2025-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of older patients undergoing major oncological surgery: Insights from the Geriatric Surgery Verification Program","authors":"Omid Salehi ,&nbsp;Irving Zhao ,&nbsp;Joanna Abi Chebl ,&nbsp;Ponnandai Somasundar ,&nbsp;Lidia Vognar ,&nbsp;N. Joseph Espat ,&nbsp;Abdul Saied Calvino ,&nbsp;Steve Kwon","doi":"10.1016/j.jgo.2025.102189","DOIUrl":"10.1016/j.jgo.2025.102189","url":null,"abstract":"<div><h3>Introduction</h3><div>Studies outlining the unique burden of geriatric medical conditions and syndromes among older adults undergoing major oncological surgery are lacking, along with understanding of the goals of care for this population.</div></div><div><h3>Materials and Methods</h3><div>We conducted a single-institutional review of the initial 50 patients who enrolled in the American College of Surgeons' Geriatric Surgery Verification Program (GSV) program implemented for those ≥65 years undergoing major oncological surgery during the year 2023. Patient variables were categorized into four domains - somatic, functional, psychological, and social. The impact of GSV was analyzed by comparing the GSV cohort to historical controls from 2021 using patients' goals of care as the outcome of interest.</div></div><div><h3>Results</h3><div>The mean age of participants was 75.4 years (± 7.5). They were mostly White (72 %), English-speaking (78 %), with similar distribution of sex (54 % female). In the somatic category, nearly 40 % were at moderate to high nutrition risk and 61.5 % had a Geriatric 8 score of ≤14. In the functional category, 34.7 % used a cane or walker, 6.4 % had history of falls, and 22.4 % had some degree of frailty. In the psychological category, &gt;70 % reported some degree of depression. Delirium risk factors were identified in 43 % of the patients. In the social category, more than half (54.3 %) of patients were never married, widowed, or divorced. Financial distress screening was positive in 23.3 %. In regard to goals of care, most patients (79.3 %) reported wanting to maintain independence while only 37.9 % reported extending life as primary concern. Using a composite adverse outcome (CAE) variable incorporating 30-day mortality and institutionalization 30-days after discharge as surrogate for these goals, we found that GSV group had an 8.0 % 30-day CAE rate compared to 28.9 % in the historical controls (<em>p</em> = 0.01).</div></div><div><h3>Discussion</h3><div>We found high proportions of patients with low G8 score, frailty, perioperative risk of falls and delirium, lack of social support, and financial distress. To meet the care goals of this population, a comprehensive geriatric surgery program is essential to preoperatively capture and mitigate risk factors.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102189"},"PeriodicalIF":3.0,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143006687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of age and performance status with adverse events in older adults with diffuse large B-cell lymphoma receiving frontline R-CHOP therapy: Alliance 151930, a secondary analysis of the phase III trial CALGB 50303","authors":"Vicki A. Morrison ,&nbsp;Jennifer Le-Rademacher ,&nbsp;Olivia Bobek ,&nbsp;Daniel Satele ,&nbsp;John P. Leonard ,&nbsp;Aminah Jatoi","doi":"10.1016/j.jgo.2025.102185","DOIUrl":"10.1016/j.jgo.2025.102185","url":null,"abstract":"<div><h3>Introduction</h3><div>Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) therapy is the standard of care for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). However, detailed delineation of toxicity data is limited and has not been examined by age. We sought to examine adverse event data in patients receiving R-CHOP from the Cancer and Leukemia Group B (CALGB) 50303 trial to determine if there were differences in grade 3+ toxicities by age cohort or ECOG performance status (PS), and if outcome was impacted by age cohort or toxicity occurrence.</div></div><div><h3>Materials and Methods</h3><div>CALGB 50303 was an intergroup phase III study for previously untreated patients with DLBCL that included R-CHOP as one of the trial arms. In the subset of 235 evaluable, seemingly fit patients receiving R-CHOP on this trial, data regarding the occurrence of grade 3+ hematologic and non-hematologic toxicities by treatment arm, as well as completion of protocol therapy, overall response rate (ORR), and survival outcome parameters were collected and analyzed for Alliance A151930.</div></div><div><h3>Results</h3><div>Data were available for further analysis from 235 of 243 patients evaluable for safety, i.e., those who received R-CHOP therapy on this trial, with 165 being &lt;65 years of age, and 70 ≥ 65 years of age. There was an increased rate of grade 3+ non-hematologic (but not hematologic) toxicities in the older age cohorts, after controlling for disease stage and performance status (<em>p</em> &lt; 0.001). One-year and three-year overall survival (OS) were inferior in patients ≥65 years of age, compared to those &lt;65 years of age; there was no difference in one-year or in three-year progression-free survival (PFS) between the age cohorts.</div></div><div><h3>Discussion</h3><div>Standard frontline therapy with R-CHOP can be effectively administered to an older age cohort. We found more grade 3+ non-hematologic, but not hematologic, toxicities in older patients. These data can be used in clinical trial and real-world settings to identify at-risk DLBCL subgroups for which pro-active measures can be utilized to ensure completion of therapy and optimization of clinical outcomes.</div><div><span><span>Clinicaltrials.gov</span><svg><path></path></svg></span> Identifier: <span><span>NCT00118209</span><svg><path></path></svg></span> (CALGB 50303).</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102185"},"PeriodicalIF":3.0,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relevance of diabetes mellitus as a confounding variable in chemotherapy outcomes","authors":"Amir Reza Akbari ,&nbsp;Benyamin Alam","doi":"10.1016/j.jgo.2025.102188","DOIUrl":"10.1016/j.jgo.2025.102188","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102188"},"PeriodicalIF":3.0,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}